Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of obinutuzumab + chlorambucil versus rituximab + chlorambucil versus chlorambucil in previously untreated CLL with comorbidities
NL-OMON39141Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab, rituximab and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Nov 2010; status: recruiting.
02
Drugs
obinutuzumabrituximabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON39141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39141.